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ANOVAanalysis of variance*Atg7*^Δβ\ cell^beta cell-specific *Atg7*-deficientAUCarea-under the curveDPP-4dipeptidyl peptidase-4ELISAenzyme-linked immunosorbent assayERendoplasmic reticulumGLP-1glucagon-like peptide-1GSISglucose-stimulated insulin secretionKRBKrebs-Ringer BicarbonateHGhigh glucoseIHCimmunohistochemicalIPGTTintraperitoneal glucose tolerance testITTinsulin tolerance testLGlow glucoseNSno significant differenceRT-PCRreal time polymerase chain reactionT2DMtype 2 diabetes mellitus

Introduction {#s0001}
============

Pancreatic islets are composed of several hormone-releasing cell types, including α cells and β cells. It is known that different types of islet cells interact with each other *via* a paracrine mechanism.[@cit0001] Glucagon-like peptide-1 (GLP-1), one of the incretin hormones, stimulates insulin secretion in β cells, inhibits glucagon release in α cells, and lowers blood glucose levels in a glucose-dependent manner.[@cit0002] Currently, incretin-based therapies such as GLP-1 receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors, which inhibit GLP-1 degradation and prolong its effects, are important treatment regimens for type 2 diabetes mellitus (T2DM).[@cit0003] In addition, incretin-based therapy has been reported to regenerate β cells and to inhibit β cell apoptosis in some animal models.[@cit0002] However, it is unclear whether incretin-based therapy affects the α cell mass.[@cit0004] A small human autopsy study described hyperplasia of pancreatic α cells in T2DM patients treated with incretin therapy.[@cit0005] However, extensive preclinical studies in rodents and nonhuman primates failed to detect α cell hyperplasia and even reported a decrease in α cell mass as a result of incretin therapy,[@cit0006] including vildagliptin,[@cit0009] a DPP-4 inhibitor.

Autophagy is a lysosomal degradation pathway that is essential for cell survival, differentiation, development, homeostasis, and the control of cellular metabolism, including in pancreatic β cells.[@cit0011] The β cell-specific autophagy-deficient mice by *Atg7* deletion (*Atg7*^Δβ\ cell^ mice) showed glucose intolerance and hypoinsulinemia.[@cit0012] Decreased β cell function and mass were observed in the mice, and were associated with a distended endoplasmic reticulum (ER), suggesting ER stress and mitochondrial dysfunction in the β cells.[@cit0012] Furthermore, autophagy deficiency was shown to contribute to β cell dysfunction and β cell loss in human T2DM.[@cit0016] Therefore, it is important to consider the effects of autophagy deficiency in the management of T2DM. There is one report on the use of incretin therapy in *Atg7*^Δβ\ cell^ mice.[@cit0017] Exendin-4, a GLP-1 receptor agonist, decreased β cell death, increased insulin secretion, and improved glucose intolerance in *Atg7*^Δβ\ cell^ mice. However, the influence on α cells, another target of GLP-1, was not described.

Therefore, we evaluated the long-term effects of a DPP-4 inhibitor on α cell mass and function in β cell-specific autophagy-deficient mice, to further examine the role of β cell autophagy in incretin effects.

Results {#s0002}
=======

Vildagliptin enhanced insulin secretion and improved glucose intolerance in Atg7^Δβ\ cell^mice {#s0002-0001}
----------------------------------------------------------------------------------------------

In the *Atg7*^Δβ\ cell^ mice, body weights were slightly lower and fed blood glucose levels were higher than those of wild-type mice, regardless of treatment (p \< 0.005; [Fig. 1A and B](#f0001){ref-type="fig"}). In each mouse genotypes, the vildagliptin treatment did not affect these variables. However, according to the intraperitoneal glucose tolerance test (IPGTT), vildagliptin significantly reduced glucose intolerance in the *Atg7*^Δβ\ cell^ mice ([Fig. 1C and D](#f0001){ref-type="fig"}). There was no difference in glucose tolerance by the vildagliptin treatment in wild-type mice. As previously reported,[@cit0017] vildagliptin significantly increased fasting serum insulin levels in both genotypes ([Fig. 1E](#f0001){ref-type="fig"}). Insulin tolerance test (ITT) results demonstrated no significant differences among the groups ([Fig. 1F and G](#f0001){ref-type="fig"}), suggesting comparable insulin actions. Figure 1.*In vivo* effects of vildagliptin on *Atg7*^Δβ\ cell^ mice. During the 12-week experiments, (**A**) body weights and (**B**) fed blood glucose levels of the mice were monitored weekly. (**C**) After 12 weeks of vildagliptin treatment, IPGTT was performed, and (**D**) the area-under the curve (AUC) of IPGTT was calculated (n \> 30 in each group). (**E**) Fasting serum insulin levels (n \> 7 in each group) were measured. (**F**) ITT and (**G**) the AUC (n \> 6 in each group) were examined. In (**A**)--(**C**) and (**F**), repeated measures ANOVA and post-hoc Tukey\'s HSD test were performed among the 4 groups: \# indicates significant difference (p \< 0.005) between wild-type and *Atg7*^Δβ\ cell^ mice regardless of treatment; \* indicates significant difference (p \< 0.05) of the control-*Atg7*^Δβ\ cell^ group from the other 3 groups. In (**D**), (**E**) and (**G**), Student\'s *t* tests were performed between control and vildagliptin groups in each mouse genotype; NS indicates no significant difference.

Vildagliptin blunted glucose-induced glucagon suppression in Atg7^Δβ\ cell^ mice {#s0002-0002}
--------------------------------------------------------------------------------

Glucose loading significantly suppressed serum glucagon levels in both mouse genotypes ([Fig. 2A](#f0002){ref-type="fig"}). However, the glucose-induced glucagon suppression disappeared in the vildagliptin-treated *Atg7*^Δβ\ cell^ mice. Next, glucose stimulation of isolated islets was done *ex vivo* ([Fig. 2B](#f0002){ref-type="fig"}). Vildagliptin induced significant glucagon suppression by high glucose in the wild-type islets, while it did not in the *Atg7*^Δβ\ cell^ islets. The glucagon suppression index calculated from the *ex vivo* study demonstrated different responses to vildagliptin between the genotypes ([Fig. 2C](#f0002){ref-type="fig"}). Figure 2.Glucose-induced glucagon suppression by vildagliptin was impaired in *Atg7*^Δβ\ cell^ islets. (**A**) After 12 weeks of vildagliptin treatment, serum was obtained before and 15 min after glucose loading, and glucagon levels were measured (n \> 7 in each group). (**B**) Islets were isolated (n \> 10 in each group), and glucose stimulation was performed. Supernatant glucagon levels were measured and adjusted by the cellular protein concentrations. (**C**) Suppression index of glucagon was calculated by the ratio of supernatant glucagon levels during HG for 1 h to those during LG for 1 h, and was compared between control and vildagliptin groups in each mouse genotype by the Student\'s *t* tests. HG, high glucose (15 mM); LG, low glucose (1.5 mM); NS, no significant difference \* indicates significant difference (p \< 0.05) by paired *t*-tests between before and after glucose stimulation.

Vildagliptin affected glucagon synthesis but not α cell mass in Atg7^Δβ\ cell^ mice {#s0002-0003}
-----------------------------------------------------------------------------------

We assessed the α cell mass using point counting after immunohistochemical (IHC) staining for glucagon in pancreas sections ([Fig. 3A](#f0003){ref-type="fig"}). Morphologies, distributions, and masses of α cells were comparable regardless of genotypes or vildagliptin treatment ([Fig. 3B](#f0003){ref-type="fig"}). Quantitative real-time polymerase chain reaction (RT-PCR) with isolated islets demonstrated that mRNA expression levels of glucagon decreased in the wild-type islets while mRNA increased in the *Atg7*^Δβ\ cell^ islets after vildagliptin treatment ([Fig. 3C](#f0003){ref-type="fig"}). Changes in pancreatic glucagon contents by vildagliptin were opposite to the changes in glucagon transcripts in both mouse genotypes, although they were not significant ([Fig. 3D](#f0003){ref-type="fig"}). Figure 3.Effects of vildagliptin on the α cell mass and glucagon synthesis in *Atg7*^Δβ\ cell^ mice. (**A**) Pancreas sections were stained with the anti-glucagon antibody. Representative images of islets from control (left) and vildagliptin-treated (right) *Atg7*^Δβ\ cell^ mice are shown (scale bar, 100 μm). (**B**) The α cell mass was calculated by point counting (n = 4∼5 in each group). (**C**) The mRNA expression of glucagon compared to that of GAPDH in the islets was assessed by quantitative RT-PCR (n \> 6 in each group). (**D**) Pancreatic glucagon contents were measured from pancreatic extracts (n \> 5 in each group). Student\'s *t* tests were used between control and vildagliptin groups in each mouse genotype; NS indicates no significant difference.

Glucose-stimulated cAMP responses were blunted in Atg7^Δβ\ cell^ islets exposed to exendin-4 in vitro {#s0002-0004}
-----------------------------------------------------------------------------------------------------

Long-term administration of vildagliptin regulated α cell function to produce and secret glucagon *in vivo*. However, the cause of blunted glucose-induced glucagon suppression remains uncertain. Therefore, we examined GLP-1 signaling using *in vitro* exendin-4 treatments. Because cAMP is a key mediator of the GLP-1 pathway,[@cit0018] we determined if the cAMP response correlated with autophagy status. Although high glucose was challenged in the presence of exendin-4, cAMP did not increase in the *Atg7*^Δβ\ cell^ islets, unlike in the wild-type islets ([Fig. 4A](#f0004){ref-type="fig"}). However, an increase of ATP by high glucose levels in the presence of exendin-4 was unaffected regardless of β cell autophagy status ([Fig. 4B](#f0004){ref-type="fig"}). Because cAMP is synthesized from ATP by adenylyl cyclase through the GLP-1 receptor,[@cit0018] these findings suggested that GLP-1 signaling was impaired in the autophagy-deficient islets. Figure 4.Glucose-stimulated cAMP production by incretin was impaired in *Atg7*^Δβ\ cell^ islets. The *Atg7*^Δβ\ cell^ and wild-type islets were treated with or without 50 nM of exendin-4 *in vitro* for 2 h (n of experiments \> 6), and then glucose stimulation was performed. Cellular cAMP (**A**), and ATP contents (**B**) were measured under low glucose (LG, 1.5 mM) or high glucose (HG, 15 mM), and adjusted by cellular protein. \* indicates significant difference (p \< 0.05) by paired *t*-tests between LG and HG. NS indicates no significant difference.

Discussion {#s0003}
==========

In this study, and as previously reported, the effects of long-term vildagliptin treatment on glucose homeostasis of *Atg7*^Δβ\ cell^ mice was favorable,[@cit0017] as shown by improved glucose tolerance from enhanced insulin secretion. However, the well-known incretin effect of glucose-induced glucagon suppression was abrogated ([Fig. 2A--C](#f0002){ref-type="fig"}). Therefore, we can infer that β cell autophagy has a role in the incretin effects on α cells.

Constitutive autophagy deficiency in β cells did not affect α cell morphology and mass ([Fig. 3A and B](#f0003){ref-type="fig"}), although the number of mice tested was too small to detect slight differences. However, autophagy deficiency in β cells did affect α cell function involving incretin. The expression of the glucagon transcript was increased by vildagliptin in the islets with autophagy-deficient β cells, contrary to in the wild-type islets ([Fig. 3C](#f0003){ref-type="fig"}). In contrast, pancreatic glucagon content was not increased by vildagliptin in *Atg7*^Δβ\ cell^ mice ([Fig. 3D](#f0003){ref-type="fig"}). In the wild-type mice, in spite of the suppressed mRNA expression by vildagliptin, pancreatic contents did not decrease. These findings can be interpreted as follows. First, translational processes might be impaired in the autophagy-deficient islets, which could reduce the increase of glucagon peptides. Second, glucagon secretory processes might not be adequately inhibited by vildagliptin in the autophagy-deficient islets, which could also contribute to the lack of an increase of pancreatic contents, along with no-decrease of serum glucagon levels by glucose stimulation ([Fig. 2A](#f0002){ref-type="fig"}). However, the discrepancy between glucagon mRNA levels and glucagon contents could have come from the experimental methods used. While glucagon mRNA levels were measured with isolated islets, glucagon contents were measured with whole pancreatic extracts. Comparable pancreatic weights (data not shown) and α cell masses ([Fig. 3B](#f0003){ref-type="fig"}) among the groups may have prevented erroneous results, but islet isolation procedures could have still affected the discrepancy. The effects of autophagy on incretin-stimulated glucagon production and secretion in the islets have not been previously reported, and the mechanisms require further verification.

Glucagon secretion is regulated by circulating insulin and glucose.[@cit0001] Therefore, our *in vivo* observations must have been affected by the hyperglycemia present in the *Atg7*^Δβ\ cell^ mice, although the hyperglycemia was mild ([Fig. 1B](#f0001){ref-type="fig"}). Therefore, we performed *in vitro* experiments to evaluate the role of autophagy in the GLP-1 pathway, to exclude the effects of hyperglycemia. It is well-known that GLP-1 potentiates glucose-stimulated cAMP increases in β cells, and that this contributes to insulin secretion in a glucose-dependent manner.[@cit0018] However, in the *Atg7*^Δβ\ cell^ islets, we did not observe the cAMP response to glucose stimulation in the presence of exendin-4 ([Fig. 4A](#f0004){ref-type="fig"}). Because we measured cAMP in whole islets, it was not possible to identify the cAMP response according to cell types. Although incretin induced cAMP in β cells and α cells *via* incretin receptors,[@cit0020] most of the mouse islets were composed of β cells, therefore the cAMP response in the mouse islets represents the response in the autophagy-deficient β cells. Generation of ATP, the precursor of cAMP, was not be affected by autophagy status in β cells ([Fig. 4B](#f0004){ref-type="fig"}). This suggested that constitutive autophagy in β cells had a role in cAMP generation from ATP in response to GLP-1. The possible causes of impaired cAMP generation, including GLP-1 receptor desensitization[@cit0021] and adenylyl cyclase down-regulation,[@cit0022] could have been affected by autophagy deficiency.

One concern with the use of autophagy-deficient islets in this study is that they are insulin deficient.[@cit0012] Glucagon secretion is closely regulated by insulin.[@cit0019] However, according to Abe *et al*,[@cit0017] exendin-4 increased glucose-dependent insulin secretion in the same mouse model, suggesting that insulin response to incretin was preserved even in autophagy-deficient β cells. Therefore, we suggest that β cell-specific autophagy deficiency directly affects α cell function, although indirect insulin effects cannot be excluded completely by the current data.

A limitation of this study design is that there could be confounding effects by genetic modulation. First, RIP-*Cre* mice can show *Cre* expression in the brain, or human growth hormone minigenes,[@cit0023] could affect the experimental results. The lower body weights in the *Atg7*^Δβ\ cell^ mice ([Fig. 1A](#f0001){ref-type="fig"}) are consistent with this possibility, although we did not study the diet. Second, the mixed background of the Balb/c mice could have affected islet function, despite the use of littermates.

In summary, we found that long-term vildagliptin treatment failed to suppress glucagon secretion after glucose loading in the *Atg7*^Δβ\ cell^ mice *in vivo* and *ex vivo*, and was associated with changes in α cell function of glucagon production. Impaired cAMP responses and resultant changes in insulin around α cells may have contributed to these results.[@cit0019] GLP-1 receptor agonists and DPP-4 inhibitors are known to inhibit glucagon secretion most likely *via* GLP-1 receptor--dependent stimulation of somatostatin secretion.[@cit0004] A recent study reported that both insulin and somatostatin were required in glucose-inhibited glucagon secretion.[@cit0025] Therefore, β cell autophagy may also have a role in somatostatin secretion. DPP-4 expression on the islet cell surface may also have influenced our results.[@cit0004]

In conclusion, β cell autophagy is required for the incretin effects on cAMP generation and the glucagon suppression in response to glucose.

Material and Methods {#s0004}
====================

Animals {#s0004-0001}
-------

*Atg7*^F/F^ mice (C57Bl/6J background) were from Professor Masaaki Komatsu,[@cit0026] and were backcrossed with the Balb/c mouse strain. Mice with backcross numbers over 3 were used for the study, and were compared among the littermates. RIP-*Cre* mice (C57Bl/6J background) were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). *Atg7*^F/F^ mice were crossed with RIP-*Cre* mice to generate *Atg7*^Δβ\ cell^ mice (mixed background of C57Bl/6J and Balb/c). RIP-*Cre* littermates and *Atg7*^F/F^ littermates were used as wild-type controls. Male mice were fed standard chow diets, and were randomized into control and vildagliptin groups at 8 weeks of age. In the vildagliptin group, vildagliptin was administered *via* drinking water (0.3 mg/mL) for 12 weeks.[@cit0009] The fed blood glucose levels and body weights were monitored weekly using a glucometer (One Touch, Johnson & Johnson, Milpitas, CA, USA) and standard scale, respectively. All animal experiments were conducted in accordance with the institutional guidelines of Seoul National University Hospital.

IPGTT and ITT {#s0004-0002}
-------------

After completion of the 12 week vildagliptin or vehicle administration at 20 weeks of age, IPGTT and ITT were performed. The ITT was performed after 6 h of fasting, with a 0.75 unit/kg (body weight) intraperitoneal insulin injection, followed by serial monitoring of blood glucose for 60 min. The IPGTT was performed after overnight fasting, with a 1 g/kg (body weight) intraperitoneal glucose injection, followed by serial glucose monitoring. During the IPGTT, serum was also obtained from retro-orbital blood samples to measure insulin (enzyme-linked immunosorbent assay (ELISA) kit, ALPCO, Salem, MA, USA) and glucagon concentrations (ELISA kit, R&D System Inc., Minneapolis, MN, USA).

Ex vivo isolated islet experiments {#s0004-0003}
----------------------------------

Pancreatic islets were isolated from overnight fasted mice using the collagenase digestion technique.[@cit0012] For the glucose-regulated glucagon secretion assay, isolated pancreatic islets were starved in Krebs-Ringer bicarbonate (KRB) buffer containing 0.2% bovine serum albumin and 1.5 mM glucose for 1 h at 37°C. Then, the media was replaced with KRB containing 1.5 mM or 15 mM glucose. After a 1 h incubation, the supernatant was collected for the measurement of glucagon (ELISA kit, R&D System, Inc.), and the islets were harvested for measurement of cellular protein concentrations, ATP (Sigma-Aldrich, St Louis, MO, USA), and cAMP (Cell Biolabs, Inc., San Diego, CA, USA). The suppression index for glucagon was calculated using the supernatant glucagon levels obtained from islets incubated in 15 mM glucose divided by the glucagon level from supernatant incubated in 1.5 mM glucose. Exendin-4 (Sigma-Aldrich), a GLP-1 receptor agonist, was added for 2 h in some *in vitro* experiments.

Estimation of α cell mass {#s0004-0004}
-------------------------

The pancreas was embedded in paraffin and sectioned to a thickness of 4 μm. IHC staining was performed with the anti-glucagon antibody (Sigma-Aldrich), and the α cell mass was then estimated by point counting.[@cit0012] In brief, the point numbers of glucagon-stained areas were counted at a magnification of 400× using a 48-point grid. The relative α cell area was calculated by dividing the point number of the glucagon-stained area by the point number over the entire pancreatic tissue sample on the same section. Two sections, separate from each other by 20 μm per mouse, were used for the mean relative area determination. The average number of islets was 20 ± 10 per section. The α cell mass was then estimated by multiplying α cell relative area by the pancreas weight.

Quantitative real-time polymerase chain reaction (RT-PCR) of glucagon mRNA {#s0004-0005}
--------------------------------------------------------------------------

Total RNA was isolated from the islets, and the cDNA was synthesized and amplified using the SYBR Premix Ex Taq polymerase (TaKaRa, Otsu, Japan). The quantitative RT-PCR was performed, and analysis was performed using the LightCycler^®^ 96 Real-Time PCR System (Roche, Mannheim, Germany). The forward primer sequence for glucagon was 5′- TGAAGACAAACGCCACTCAC-3′ and the reverse primer sequence was 5′- CAGCATGCCTCTCAAATTTCA-3′. Those of GAPDH used for standardization were 5′-AGGTCGGTGTGAACGGATTTG-3′ and 5′-TGTAGACCATGTAGTTGAGGTCA-3′, respectively.

Pancreatic glucagon contents {#s0004-0006}
----------------------------

Pancreatic hormones were extracted using a previously published method.[@cit0028] ELISA was performed to measure the glucagon levels of the pancreatic extracts (R&D System, Inc.). The concentrations were normalized by pancreas weights.

Statistical analysis {#s0004-0007}
--------------------

All data are expressed as means ± standard error of the mean. A repeated measures analysis of variance (ANOVA) and subsequent post-hoc Tukey\'s Honestly Significant Difference (HSD) test were used for serial changes in body weight and blood glucose levels ([Fig. 1](#f0001){ref-type="fig"}). Student\'s *t* tests were employed to compare vildagliptin effects in the wild-type or in the knock-out groups. Paired *t*-tests were performed to evaluate glucagon, cAMP, and ATP responses to glucose stimulation. All analyses were performed using SPSS 14.0 for Windows (SPSS Inc., Chicago, IL, USA).
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